WS #14664
TSMC is signaling strong pricing power with planned wafer price hikes of ~5% starting in 2027, supporting the bullish thesis for the semiconductor equipment and foundry sector. Simultaneously, AI biotech Enveda secured $311M in funding, validating the intersection of AI and drug discovery. However, this AI advancement has a negative spillover effect on pure-play gene-editing stocks like Editas and CRISPR Therapeutics, which fell on fears of AI-driven technological displacement.
Semiconductor Supply & AI
TSMC is signaling strong pricing power with planned wafer price hikes of ~5% starting in 2027, supporting the bullish thesis for the semiconductor equipment and foundry sector. Simultaneously, AI biotech Enveda secured $311M in funding, validating the intersection of AI and drug discovery. However, this AI advancement has a negative spillover effect on pure-play gene-editing stocks like Editas and CRISPR Therapeutics, which fell on fears of AI-driven technological displacement.